Category Press Releases

CB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target

CB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target

Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development of CD19 and CD22-targeted ARTEMIS® T-cell therapies for cancer and…

Read MoreCB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target
Repligen Acquires 908 Devices' Bioprocessing Analytics Portfolio for $70 Million

Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million

Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million Repligen Corporation (Nasdaq: RGEN), a leading life sciences company specializing in bioprocessing technology, has announced the acquisition of 908 Devices Inc.’s (Nasdaq: MASS) desktop portfolio, further strengthening its position in…

Read MoreRepligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million
TEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy

TEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy

TEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy BeiGene, Ltd. a global oncology company that has announced its intent to change its name to BeOne Medicines Ltd., recently revealed that the U.S. Food and Drug Administration (FDA)…

Read MoreTEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy
FairJourney Biologics Acquires Charles River's South San Francisco Site

FairJourney Biologics Acquires Charles River’s South San Francisco Site

FairJourney Biologics Acquires Charles River’s South San Francisco Site FairJourney Biologics S.A., a global leader in antibody discovery and optimization, has announced the successful acquisition of the South San Francisco site from Charles River Laboratories International, Inc. This strategic acquisition…

Read MoreFairJourney Biologics Acquires Charles River’s South San Francisco Site
Surescripts 2024 Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access

Surescripts 2024 Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access

Surescripts 2024 Annual Impact Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access Surescripts, the nation’s leading health information network, has released its highly anticipated 2024 Annual Impact Report, underscoring the transformative advancements in health intelligence sharing.…

Read MoreSurescripts 2024 Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access

Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program

Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has officially opened applications for the 2025-2026 academic year of Route 79, The Duchenne…

Read MoreSarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program